{"protocolSection": {"identificationModule": {"nctId": "NCT00541775", "orgStudyIdInfo": {"id": "0431-801"}, "secondaryIdInfos": [{"id": "2007_623"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "Safety/Efficacy of Sitagliptin in Patient w/ Type 2 Diabetes (0431-801)", "officialTitle": "A Multicenter, Double-Blind, Placebo and Active Controlled, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin 100 mg Once Daily in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin Monotherapy"}, "statusModule": {"statusVerifiedDate": "2015-08", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-06"}, "primaryCompletionDateStruct": {"date": "2007-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-10-05", "studyFirstSubmitQcDate": "2007-10-05", "studyFirstPostDateStruct": {"date": "2007-10-10", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-05-17", "resultsFirstSubmitQcDate": "2010-05-17", "resultsFirstPostDateStruct": {"date": "2010-06-17", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-08-21", "lastUpdatePostDateStruct": {"date": "2015-08-24", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this study is to test the safety and effectiveness of sitagliptin in patients with type 2 diabetes."}, "conditionsModule": {"conditions": ["Type 2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 273, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Sitagliptin", "type": "EXPERIMENTAL", "description": "sitagliptin 100 mg", "interventionNames": ["Drug: Sitagliptin", "Drug: Comparator: Metformin"]}, {"label": "Rosiglitazone", "type": "ACTIVE_COMPARATOR", "description": "rosiglitazone 8 mg", "interventionNames": ["Drug: Comparator: Rosiglitazone", "Drug: Comparator: Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "placebo", "interventionNames": ["Drug: Comparator: Placebo", "Drug: Comparator: Metformin"]}], "interventions": [{"type": "DRUG", "name": "Sitagliptin", "description": "Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.", "armGroupLabels": ["Sitagliptin"], "otherNames": ["Januvia"]}, {"type": "DRUG", "name": "Comparator: Rosiglitazone", "description": "Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.", "armGroupLabels": ["Rosiglitazone"], "otherNames": ["Avandia"]}, {"type": "DRUG", "name": "Comparator: Placebo", "description": "placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Comparator: Metformin", "description": "Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of \\>= 1500 mg.", "armGroupLabels": ["Placebo", "Rosiglitazone", "Sitagliptin"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Hemoglobin A1C (A1C) at Week 18", "description": "A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.\n\nThe study hypothesis comparison was between sitagliptin versus placebo.", "timeFrame": "Baseline and 18 Weeks"}], "secondaryOutcomes": [{"measure": "Fasting Plasma Glucose (FPG) at Week 18", "description": "The change from baseline is the Week 18 FPG minus the Week 0 FPG.", "timeFrame": "Baseline and 18 Weeks"}, {"measure": "2-hour Post-meal Glucose (PMG) at Week 18", "description": "The change from baseline is the Week 18 PMG minus the Week 0 PMG.", "timeFrame": "Baseline and 18 Weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient has Type 2 diabetes\n* Currently taking metformin \\>1500 mg/day for at least 10 weeks\n* Male or female\n\nExclusion Criteria:\n\n* Patient has peripheral edema\n* History of type 1 diabetes\n* Patient required insulin within prior 8 weeks\n* Have participated or are currently participating in another study with an investigational compound or device within 12 weeks of starting this study\n* Participating in a weight loss program", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Monitor", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "referencesModule": {"references": [{"pmid": "18201203", "type": "BACKGROUND", "citation": "Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008 Sep;10(10):959-69. doi: 10.1111/j.1463-1326.2007.00839.x. Epub 2008 Jan 14."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Patients 18-75 years of age with type 2 diabetes mellitus (T2DM) who were taking metformin monotherapy at a stable dose of \u2265 1500 mg/day for at least 10 weeks and had inadequate glycemic control (hemoglobin A1C \u2265 7.0% and \u226411%) were eligible to participate.", "recruitmentDetails": "First Patient In: 16-June-2006. Last Patient Last Visit: 2-March-2007. 13 medical clinics in 3 countries in Europe and 23 in 4 countries in the rest of the world", "groups": [{"id": "FG000", "title": "Sitagliptin", "description": "The Sitagliptin group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg and placebo matching rosiglitazone q.d. (once-daily) with metformin (\u22651500 mg/day)."}, {"id": "FG001", "title": "Rosiglitazone", "description": "The Rosiglitazone group includes data from patients randomized to receive treatment with oral tablets of rosiglitazone 8 mg and placebo matching sitagliptin q.d. in combination with metformin (\u22651500 mg/day)."}, {"id": "FG002", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of placebo matching sitagliptin and placebo matching rosiglitazone q.d. with metformin (\u22651500 mg/day)."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "94"}, {"groupId": "FG001", "numSubjects": "87"}, {"groupId": "FG002", "numSubjects": "92"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "85"}, {"groupId": "FG001", "numSubjects": "85"}, {"groupId": "FG002", "numSubjects": "84"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "8"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "3"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject and Other", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Sitagliptin", "description": "The Sitagliptin group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg and placebo matching rosiglitazone q.d. (once-daily) with metformin (\u22651500 mg/day)."}, {"id": "BG001", "title": "Rosiglitazone", "description": "The Rosiglitazone group includes data from patients randomized to receive treatment with oral tablets of rosiglitazone 8 mg and placebo matching sitagliptin q.d. in combination with metformin (\u22651500 mg/day)."}, {"id": "BG002", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of placebo matching sitagliptin and placebo matching rosiglitazone q.d. with metformin (\u22651500 mg/day)."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "94"}, {"groupId": "BG001", "value": "87"}, {"groupId": "BG002", "value": "92"}, {"groupId": "BG003", "value": "273"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "55.2", "spread": "9.8"}, {"groupId": "BG001", "value": "54.8", "spread": "10.5"}, {"groupId": "BG002", "value": "55.3", "spread": "9.3"}, {"groupId": "BG003", "value": "55.1", "spread": "9.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "32"}, {"groupId": "BG002", "value": "38"}, {"groupId": "BG003", "value": "112"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "52"}, {"groupId": "BG001", "value": "55"}, {"groupId": "BG002", "value": "54"}, {"groupId": "BG003", "value": "161"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "White", "categories": [{"measurements": [{"groupId": "BG000", "value": "57"}, {"groupId": "BG001", "value": "51"}, {"groupId": "BG002", "value": "56"}, {"groupId": "BG003", "value": "164"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}, {"title": "Asian", "categories": [{"measurements": [{"groupId": "BG000", "value": "36"}, {"groupId": "BG001", "value": "33"}, {"groupId": "BG002", "value": "36"}, {"groupId": "BG003", "value": "105"}]}]}, {"title": "Other", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "3"}]}]}]}, {"title": "Fasting Plasma Glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "157.5", "spread": "31.4"}, {"groupId": "BG001", "value": "156.9", "spread": "31.6"}, {"groupId": "BG002", "value": "160.0", "spread": "37.4"}, {"groupId": "BG003", "value": "158.1", "spread": "33.5"}]}]}]}, {"title": "Hemoglobin A1C (A1C)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent of glycosylated hemoglobin (A1C)", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "7.8", "spread": "1.0"}, {"groupId": "BG001", "value": "7.7", "spread": "0.8"}, {"groupId": "BG002", "value": "7.7", "spread": "0.9"}, {"groupId": "BG003", "value": "7.7", "spread": "0.9"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Hemoglobin A1C (A1C) at Week 18", "description": "A1C is measured as percent. Thus, this change from baseline reflects the Week 18 A1C percent minus the Week 0 A1C percent.\n\nThe study hypothesis comparison was between sitagliptin versus placebo.", "populationDescription": "The all patients treated population included all patients who took at least one dose of study medication and had both a baseline measurement and at least one post-randomization measurement for this outcome. Missing data were imputed using the last observation carried forward (LOCF) method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent of glycosylated hemoglobin (A1C)", "timeFrame": "Baseline and 18 Weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "The Sitagliptin group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg and placebo matching rosiglitazone q.d. (once-daily) with metformin (\u22651500 mg/day)."}, {"id": "OG001", "title": "Rosiglitazone", "description": "The Rosiglitazone group includes data from patients randomized to receive treatment with oral tablets of rosiglitazone 8 mg and placebo matching sitagliptin q.d. in combination with metformin (\u22651500 mg/day)."}, {"id": "OG002", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of placebo matching sitagliptin and placebo matching rosiglitazone q.d. with metformin (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "91"}, {"groupId": "OG001", "value": "87"}, {"groupId": "OG002", "value": "88"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.73", "lowerLimit": "-0.87", "upperLimit": "-0.60"}, {"groupId": "OG001", "value": "-0.79", "lowerLimit": "-0.92", "upperLimit": "-0.65"}, {"groupId": "OG002", "value": "-0.22", "lowerLimit": "-0.36", "upperLimit": "-0.08"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<=0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis of covariance with a term for treatment, and a covariate for baseline value.", "paramType": "Mean Difference (Net)", "paramValue": "-0.51", "ciPctValue": "95", "ciLowerLimit": "-0.70", "ciUpperLimit": "-0.32", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.1"}]}, {"type": "SECONDARY", "title": "Fasting Plasma Glucose (FPG) at Week 18", "description": "The change from baseline is the Week 18 FPG minus the Week 0 FPG.", "populationDescription": "The all patients treated population included all patients who took at least one dose of study medication and had both a baseline measurement and at least one post-randomization measurement for this outcome. Missing data were imputed using the last observation carried forward (LOCF) method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and 18 Weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "The Sitagliptin group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg and placebo matching rosiglitazone q.d. (once-daily) with metformin (\u22651500 mg/day)."}, {"id": "OG001", "title": "Rosiglitazone", "description": "The Rosiglitazone group includes data from patients randomized to receive treatment with oral tablets of rosiglitazone 8 mg and placebo matching sitagliptin q.d. in combination with metformin (\u22651500 mg/day)."}, {"id": "OG002", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of placebo matching sitagliptin and placebo matching rosiglitazone q.d. with metformin (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "92"}, {"groupId": "OG001", "value": "87"}, {"groupId": "OG002", "value": "89"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-11.7", "lowerLimit": "-18.6", "upperLimit": "-4.9"}, {"groupId": "OG001", "value": "-24.5", "lowerLimit": "-31.6", "upperLimit": "-17.5"}, {"groupId": "OG002", "value": "6.1", "lowerLimit": "-0.8", "upperLimit": "13.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<=0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis of covariance with a term for treatment, and a covariate for baseline value.", "paramType": "Mean Difference (Net)", "paramValue": "-17.8", "ciPctValue": "95", "ciLowerLimit": "-27.6", "ciUpperLimit": "-8.1", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "5"}]}, {"type": "SECONDARY", "title": "2-hour Post-meal Glucose (PMG) at Week 18", "description": "The change from baseline is the Week 18 PMG minus the Week 0 PMG.", "populationDescription": "The all patients treated population included all patients who took at least one dose of study medication and had both a baseline measurement and at least one post-randomization measurement for this outcome. Missing data were imputed using the last observation carried forward (LOCF) method.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and 18 Weeks", "groups": [{"id": "OG000", "title": "Sitagliptin", "description": "The Sitagliptin group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg and placebo matching rosiglitazone q.d. (once-daily) with metformin (\u22651500 mg/day)."}, {"id": "OG001", "title": "Rosiglitazone", "description": "The Rosiglitazone group includes data from patients randomized to receive treatment with oral tablets of rosiglitazone 8 mg and placebo matching sitagliptin q.d. in combination with metformin (\u22651500 mg/day)."}, {"id": "OG002", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of placebo matching sitagliptin and placebo matching rosiglitazone q.d. with metformin (\u22651500 mg/day)."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "80"}, {"groupId": "OG001", "value": "76"}, {"groupId": "OG002", "value": "78"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-35.4", "lowerLimit": "-46.3", "upperLimit": "-24.5"}, {"groupId": "OG001", "value": "-51.3", "lowerLimit": "-62.5", "upperLimit": "-40.1"}, {"groupId": "OG002", "value": "-4.9", "lowerLimit": "-16.0", "upperLimit": "6.1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<=0.001", "statisticalMethod": "ANCOVA", "statisticalComment": "Analysis of covariance with a term for treatment, and a covariate for baseline value.", "paramType": "Mean Difference (Net)", "paramValue": "-30.5", "ciPctValue": "95", "ciLowerLimit": "-46.0", "ciUpperLimit": "-15.0", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "7.9"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Weeks 0 to 18", "description": "Safety tables are based on the All Patients as Treated (APaT) population that includes all patients who took at least one dose of study drug. One patient in the placebo group did not take any study drug. Thus, for the placebo group 92 patients are reported in the baseline characteristics and 91 patients are reported in the AE summary.", "eventGroups": [{"id": "EG000", "title": "Sitagliptin", "description": "The Sitagliptin group includes data from patients randomized to receive treatment with oral tablets of sitagliptin 100 mg and placebo matching rosiglitazone q.d. (once-daily) with metformin (\u22651500 mg/day).", "seriousNumAffected": 5, "seriousNumAtRisk": 94, "otherNumAffected": 5, "otherNumAtRisk": 94}, {"id": "EG001", "title": "Rosiglitazone", "description": "The Rosiglitazone group includes data from patients randomized to receive treatment with oral tablets of rosiglitazone 8 mg and placebo matching sitagliptin q.d. in combination with metformin (\u22651500 mg/day).", "seriousNumAffected": 5, "seriousNumAtRisk": 87, "otherNumAffected": 1, "otherNumAtRisk": 87}, {"id": "EG002", "title": "Placebo", "description": "The Placebo group includes data from patients randomized to receive treatment with oral tablets of placebo matching sitagliptin and placebo matching rosiglitazone q.d. with metformin (\u22651500 mg/day).", "seriousNumAffected": 5, "seriousNumAtRisk": 91, "otherNumAffected": 0, "otherNumAtRisk": 91}], "seriousEvents": [{"term": "Angina unstable", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 87}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 91}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 87}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 91}]}, {"term": "Intentional overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 87}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 91}]}, {"term": "Overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 87}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 91}]}, {"term": "Skin laceration", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 87}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 91}]}, {"term": "Prostate cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 87}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Syncope", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 87}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 91}]}, {"term": "Endometrial hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 87}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 91}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 87}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 91}]}], "otherEvents": [{"term": "Blood glucose increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 94}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 87}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 91}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "D000077154", "term": "Rosiglitazone"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M1677", "name": "Rosiglitazone", "asFound": "Facility", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}